Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
82626-01-5CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12JRTIDHTUMYMPRU-UHFFFAOYSA-NAlpidem is a member of imidazoles.
82626-01-5DTXSID8049046CHEMBL54349CHEBI:135649Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 1 notifications to the ECHA C&L Inventory.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Alpidem
vMost-DILI-concern
8
Withdrawn
DOI:10.1016/j.drudis.2016.02.015
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
BeschreibungAlpidem is an imidazopyridine antianxiety agent with anticonvulsant properties. It is claimed to be the first non-benzodiazepine anxiolytic to show selectivity for the omega-1 modulatory site of the GABA, receptors. Alpidem is reported to be superior to buspirone and similar to the benzodiazepines, but is significantly better tolerated with lower abuse potential.
VerwendenA peripheral benzodiazepine GABAA receptor ligand, a new anxiolytic